4
4D MOLECULAR THERAPEUTICS INC
NASDAQ: FDMT (4D Molecular Therapeutics, Inc.)
Last update: 1 hour ago11.90
-0.88 (-6.89%)
| Previous Close | 12.78 |
| Volume | 683,476 |
| Price / Sales | 8.97 |
| Price / Book | 1.73 |
| 52 Weeks Range |
| Operating Margin (TTM) | -383,007.15% |
| Diluted EPS (TTM) | -3.18 |
| Quarterly Revenue Growth (YOY) | -50.00% |
| Total Debt/Equity (MRQ) | 5.08% |
| Current Ratio (MRQ) | 12.36 |
| Operating Cash Flow (TTM) | -153.26 M |
| Levered Free Cash Flow (TTM) | -90.21 M |
| Return on Assets (TTM) | -22.18% |
| Return on Equity (TTM) | -32.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | 4D Molecular Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.77 |
Select this tab to load the latest available analysis.
|
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.88% |
| % Held by Institutions | 95.91% |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |